Literature DB >> 29684469

Imaging techniques to study drug transporter function in vivo.

Nicolas Tournier1, Bruno Stieger2, Oliver Langer3.   

Abstract

Transporter systems involved in the permeation of drugs and solutes across biological membranes are recognized as key determinants of pharmacokinetics. Typically, the action of membrane transporters on drug exposure to tissues in living organisms is inferred from invasive procedures, which cannot be applied in humans. In recent years, imaging methods have greatly progressed in terms of instruments, synthesis of novel imaging probes as well as tools for data analysis. Imaging allows pharmacokinetic parameters in different tissues and organs to be obtained in a non-invasive or minimally invasive way. The aim of this overview is to summarize the current status in the field of molecular imaging of drug transporters. The overview is focused on human studies, both for the characterization of transport systems for imaging agents as well as for the determination of drug pharmacokinetics, and makes reference to animal studies where necessary. We conclude that despite certain methodological limitations, imaging has a great potential to study transporters at work in humans and that imaging will become an important tool, not only in drug development but also in medicine. Imaging allows the mechanistic aspects of transport proteins to be studied, as well as elucidating the influence of genetic background, pathophysiological states and drug-drug interactions on the function of transporters involved in the disposition of drugs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Membrane transporters; Molecular imaging; Pharmacokinetics; Positron emission tomography; Single photon emission computed tomography

Mesh:

Substances:

Year:  2018        PMID: 29684469     DOI: 10.1016/j.pharmthera.2018.04.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  19 in total

1.  Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.

Authors:  Sarah Billington; Steven Shoner; Scott Lee; Kindra Clark-Snustad; Matthew Pennington; David Lewis; Mark Muzi; Shirley Rene; Jean Lee; Tot Bui Nguyen; Vineet Kumar; Kazuya Ishida; Laigao Chen; Xiaoyan Chu; Yurong Lai; Laurent Salphati; Cornelis E C A Hop; Guangqing Xiao; Mingxiang Liao; Jashvant D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

2.  Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?

Authors:  Louise Breuil; Solène Marie; Sébastien Goutal; Sylvain Auvity; Charles Truillet; Wadad Saba; Oliver Langer; Fabien Caillé; Nicolas Tournier
Journal:  J Cereb Blood Flow Metab       Date:  2021-09-09       Impact factor: 6.960

3.  Brain Distribution of Drugs: Brain Morphology, Delivery Routes, and Species Differences.

Authors:  Fanchon Bourasset; Sylvain Auvity; Robert G Thorne; Jean-Michel Scherrmann
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

Authors:  Hans Christian Cederberg Helms; Mie Kristensen; Lasse Saaby; Gert Fricker; Birger Brodin
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Imaging P-Glycoprotein Induction at the Blood-Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PET.

Authors:  Viktoria Zoufal; Severin Mairinger; Mirjam Brackhan; Markus Krohn; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Wanek; Nicolas Tournier; Martin Bauer; Jens Pahnke; Oliver Langer
Journal:  J Nucl Med       Date:  2019-12-05       Impact factor: 11.082

6.  Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.

Authors:  Dorra Amor; Sébastien Goutal; Solène Marie; Fabien Caillé; Martin Bauer; Oliver Langer; Sylvain Auvity; Nicolas Tournier
Journal:  EJNMMI Res       Date:  2018-08-16       Impact factor: 3.138

7.  Imaging P-Glycoprotein Function at the Blood-Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs.

Authors:  Martin Bauer; Nicolas Tournier; Oliver Langer
Journal:  Clin Pharmacol Ther       Date:  2019-03-23       Impact factor: 6.903

8.  Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography.

Authors:  Irene Hernández Lozano; Rudolf Karch; Martin Bauer; Matthias Blaickner; Akihiro Matsuda; Beatrix Wulkersdorfer; Marcus Hacker; Markus Zeitlinger; Oliver Langer
Journal:  AAPS J       Date:  2019-04-29       Impact factor: 4.009

9.  Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates.

Authors:  Solène Marie; Irene Hernández-Lozano; Louise Breuil; Charles Truillet; Shuiying Hu; Alex Sparreboom; Nicolas Tournier; Oliver Langer
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

10.  Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood-Brain Barrier in Non-Human Primates with PET.

Authors:  Lara García-Varela; Wejdan M Arif; David Vállez García; Takeharu Kakiuchi; Hiroyuki Ohba; Norihiro Harada; Tetsuro Tago; Philip H Elsinga; Hideo Tsukada; Nicola Antonio Colabufo; Rudi A J O Dierckx; Aren van Waarde; Jun Toyohara; Ronald Boellaard; Gert Luurtsema
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.